Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)

Trial Profile

Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Scleritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GATSBY
  • Most Recent Events

    • 28 Jul 2015 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
    • 28 Jul 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
    • 18 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top